FDC has launched new strength variants of its Favipiravir brands - PiFLU and Favenza, used to treat mild to moderate cases of COVID-19 in India. These prescription-only drugs will be available at all retail medical outlets and hospital pharmacies across the country, from November 1, 2020.
The 800mg version of the drugs will help reduce the number of tablets to be taken by any patient by 75%. Currently patients are required to take 18 pills on the first day followed by 8 tablets every day for the next 13 days.
FDC is engaged in manufacture of specialized formulations, and oral rehydration salts (ORS).
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1872.60 |
| Dr. Reddys Labs. | 1376.30 |
| Cipla | 1453.50 |
| Zydus Lifesciences | 1121.65 |
| Lupin | 2407.45 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: